摘要：

With the development of new immunosuppressive drugs in the last decade, outcomes in terms of graft survival after renal transplantation have improved up to 90% or more at 1 year. In this period of time, the reduction of acute rejection has been the most commonly used primary end point in clinical trials. Clinicians have often expected a parallel improvement in graft survival but have been...

展开